Patent classifications
C12N2501/72
CBL INHIBITORS AND COMPOSITIONS FOR EXPANSION OF IMMUNE CELLS
Methods and compositions using novel Cbl inhibitors enhancing expansion of immune cells to increase the efficacy of cell-based immunotherapeutics are disclosed. Also provided are cell-based immunotherapy methods and compositions.
CBL INHIBITORS AND COMPOSITIONS FOR USE IN ADOPTIVE CELL THERAPY
Methods and compositions using novel Cbl inhibitors for supporting engraftment of immune cells to increase the efficacy of cell-based immunotherapeutics are disclosed. Also provided are cell-based immunotherapy methods and compositions using novel Cbl inhibitors for the propagation of cells desirable for use in cell-based immunotherapies.
Method for Reprogramming Cell
Provided are a method for reprogramming a cell in the presence of one or more reprogramming factors, a reprogrammed cell obtained by using the method and use thereof, and a kit comprising the reprogramming factors.
METHOD OF INDUCING DEDIFFERENTIATION OF SOMATIC CELLS WITH SMALL MOLECULES TO PREPARE REJUVENATED MESENCHYMAL STEM CELLS AND USES THEREOF
A preparation method and applications of rejuvenated and regenerative fibroblasts, where the rejuvenated and regenerative fibroblasts are prepared from normal fibroblasts by inhibiting the JAK-STAT signaling pathway. The rejuvenated and regenerative fibroblasts are prepared by treating the target cells with a small molecular combination, a cytokine combination or a recombinant protein combination. This application further provides an application of the rejuvenated and regenerative fibroblasts in the reprogramming or rejuvenation of cells, tissues, organs and organisms.
METHODS FOR SELECTIVE INHIBITION OF PLURIPOTENT STEM CELLS
Provided herein are methods of reducing or eliminating undifferentiated pluripotent stem cells, where the methods comprise contacting an effective amount of a compound to a heterogeneous cell population or sample comprising or suspected of comprising differentiated cell types and undifferentiated pluripotent stem cells, whereby the contacting selectively reduces or eliminates undifferentiated pluripotent stem cells from the cell population or sample. Also provided are methods for obtaining a population of stem cell-derived cell types substantially free of undifferentiated pluripotent stem cells as well as isolated populations of such of stem cell-derived cell types.
Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
The present invention provides methods, cell cultures and differentiation media to promote differentiation of pluripotent stem cells to pancreatic endocrine cells of a mature phenotype. The resulting pancreatic endocrine cells express single hormonal insulin, PDX1, NKX6.1, and MAFA. In one or more differentiation stages, culturing may be carried out in a culture vessel at the air-liquid interface.
Methods of obtaining pancreatic endocrine cells
The present invention relates to methods of producing pancreatic endocrine cells and uses of the cells obtained using the methods. The method utilises inhibitors or combinations of factors to provide increased quantities of endocrine material, for example for transplantation purposes.
Small Molecule-Induced Method for Directly Reprogramming Human Fibroblasts into Liver Cells
This disclosure relates to a method for direct reprogramming (transdifferentiation) of human fibroblasts into hepatocytes by small molecules. A method and a small molecule composition for direct reprogramming (transdifferentiation) of human fibroblasts into hepatocytes based on a mechanism of chemically induced cell direct reprogramming are disclosed. The small molecule composition can be developed into drug or prodrugs for the treatment of hepatic fibrosis (Cirrhosis), pulmonary fibrosis and fibrosis diseases of other organ or tissue in human. This disclosure also discloses a cell transdifferentiation medium and a reagent prepared by the small molecule composition.
Methods to Enhance Tumor Immunogenicity and Compositions for Autologous Cancer Immunotherapeutic Products Using Modified Tumor Cells and Modified Dendritic Cells
The present specification provides methods for augmenting the antigenic content, especially of tumor-associated antigens (TAA), and immunogenicity of cancer cells; methods for enhancing cross-presentation in dendritic cells, compositions comprising such manipulated cells derived from single cancer patients; and methods of using those compositions as a personal immunotherapeutic product to treat the donor patient's cancer.
METHODS OF REPROGRAMMING ANIMAL SOMATIC CELLS
This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease.